Elkfork Partners’s Adamas Pharmaceuticals ADMS Stock Holding History

Elkfork Partners’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,696	Closed	-$74K	–	1074
2018 Q3	$74K	Buy	+3,696	New	+$86.8K	﹤0.01%	974

Other funds holding ADMS

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Elkfork Partners's ADMS Position: Q4 2018 in Review

Elkfork Partners sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 3,696 shares — an estimated $74K sold.

Elkfork Partners first reported a position in ADMS in Q3 2018 and held it in 1 quarter. The position peaked at $74K in Q3 2018. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

Elkfork Partners reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Elkfork Partners sold 3,696 Adamas Pharmaceuticals shares in Q4 2018, an estimated $74K.
Elkfork Partners first reported a position in Adamas Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Elkfork Partners's Adamas Pharmaceuticals position peaked at $74K in Q3 2018.
98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on Elkfork Partners's 13F filing for Q4 2018, filed 13 Feb 2019.